Art

J-GLOBAL ID：202102272390130537   Reference number：21A0828254

ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance

ROS過剰産生は骨髄腫細胞をボルテゾミブ誘発アポトーシスに感受性し,腫瘍微小環境媒介細胞耐性を軽減する【JST・京大機械翻訳】

Author (8)： Caillot Melody (INSERM, UNICAEN, Normandie Universite, F-14000 Caen, France) ,  Zylbersztejn Florence (INSERM, UNICAEN, Normandie Universite, F-14000 Caen, France) ,  Maitre Elsa (INSERM, UNICAEN, Normandie Universite, F-14000 Caen, France) ,  Maitre Elsa (Laboratoire d’Hematologie, CHU Cote de Nacre, F-14000 Caen, France) ,  Bourgeais Jerome (Service d’Hematologie Biologique, CHRU de Tours, F-37000 Tours, France) ,  Herault Olivier (Service d’Hematologie Biologique, CHRU de Tours, F-37000 Tours, France) ,  Herault Olivier (LNox, CNRS, Universite de Tours, F-37000 Tours, France) ,  Sola Brigitte (INSERM, UNICAEN, Normandie Universite, F-14000 Caen, France)
Material： Cells (Web)
Volume： 9  Issue： 11  Page： 2357  Publication year： 2020 
JST Material Number： U7155A  ISSN： 2073-4409  Document type： Article
Article type： 原著論文  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Multiple myeloma (MM) is a pla...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0828254&from=J-GLOBAL&jstjournalNo=U7155A") }}

Thesaurus term： sensitization(immunology) ,  potentiation ,  thioredoxin reductase ,  mesenchyme ,  auranofin ,  multiple myeloma ,  active oxygen ,  *apoptosis ,  coculture ,  NADPH oxidase ,  autophagy
Semi thesaurus term： 細胞株 ,  抗酸化酵素 ,  スフェロイド ,  過剰発現 , 【Automatic Indexing@JST】

Author keywords (7)： reactive oxygen species ,  resistance ,  bortezomib ,  auranofin ,  antioxidant enzymes ,  survival ,  3-D culture

JST classification (2)： Basic research of antitumor(=antineoplastic)drugs  (GW16010A) ,  Cell physiology in general  (EF02010S)

Reference (41)：

• Chim, C.S.; Kumar, S.K.; Orlowski, R.Z.; Cook, G.; Richardson, P.G.; Gertz, M.A.; Giralt, S.; Mateos, M.V.; Leleu, X.; Anderson, K.C. Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond. Leukemia 2018, 32, 252-262.
• Gandolfi, S.; Laubach, J.P.; Hideshima, T.; Chauhan, D.; Anderson, K.C.; Richardson, P.G. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017, 36, 561-584.
• Grigoreva, T.A.; Tribulovich, V.G.; Garabadzhiu, A.V.; Melino, G.; Barlev, N.A. The 26S proteasome is a multifaceted target for anti-cancer therapies. Oncotarget 2015, 6, 24733-24749.
• Röllig, C.; Knop, S.; Bornhäuser, M. Multiple myeloma. Lancet 2015, 385, 2197-2208.
• Wallington-Beddoe, C.T.; Sobieraj-Teague, M.; Kuss, B.J.; Pitson, S.M. Resistance to proteasome inhibitors and other targeted therapies in myeloma. Br. J. Haematol. 2018, 182, 11-28.

Terms in the title (9)： ROS ,  骨髄腫細胞 ,  ボルテゾミブ ,  誘発 ,  アポトーシス ,  感受性 ,  腫瘍微小環境 ,  細胞 ,  耐性